ProfileGDS5678 / 1421352_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 64% 63% 64% 70% 64% 62% 72% 59% 64% 64% 64% 63% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8483664
GSM967853U87-EV human glioblastoma xenograft - Control 23.8492164
GSM967854U87-EV human glioblastoma xenograft - Control 33.7808763
GSM967855U87-EV human glioblastoma xenograft - Control 43.8056364
GSM967856U87-EV human glioblastoma xenograft - Control 54.3793870
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.907864
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8125962
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.51972
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5212959
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8341164
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8271864
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.818664
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7787863
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8588964